Ashina, Håkan
Iljazi, Afrim
Al-Khazali, Haidar M.
Do, Thien Phu
Eigenbrodt, Anna K.
Larsen, Eigil L.
Andersen, Amalie M.
Hansen, Kevin J.
Bräuner, Karoline B.
Chaudhry, Basit Ali
Christensen, Casper E.
Amin, Faisal Mohammad
Schytz, Henrik W.
Article History
Received: 27 July 2022
Accepted: 16 September 2022
First Online: 17 October 2022
Declarations
:
: Informed written consent was obtained from each patient before conducting any study-related procedures. The study protocol was approved by the relevant ethics committee.
: Not applicable.
: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: H.A. reports personal fees from Teva. F.M.A. has been a consultant, speaker, or scientific adviser for Eli Lilly, Lundbeck, Novartis, and Teva, outside of the submitted work. H.W.S. has been a consultant, speaker, or scientific adviser for Novartis, Eli Lilly, Lundbeck, Abbvie, and Teva, outside of the submitted work. All other authors declare no competing interests.